Replies to post #84189 on Biotech Values

[flatlander_60048]

ABT Terms for stent coating

Dew do you have any idea what the terms are for ABT and Boston Scientific to compensate NVS for the mtor inhibitor used to coat the stent Xience?

Is there anything that obligates NVS not to provide this drug to competing stents? NVS reports do not seem to break out the compensation.

Thanks

FL

[DewDiligence]

Scanning ABT’s 3Q09 PR, which just hit the wires, and the first place I looked was the sales line for Humira. (I’ll have more to say on the 3Q09 results later.)

http://finance.yahoo.com/news/Abbott-Reports-165-Percent-prnews-3645456301.html/print?x=0

Humira continues to be a monster: worldwide sales are running at an annualized rate of $6B and grew 32% year-over-year in constant currencies (24% in dollars).

$6B drugs growing at more than 30% do not come along every day and ABT says, “You ain’t seen nothing yet!”

[DewDiligence]

ABT ‘Mini’ ReadMeFirst

[Updates:
3Q09 financial results;
Xience SPIRIT IV data from TCT 2009;
judge refuses to reduce Humira patent damages.]


Finances and outlook
#msg-42530480 3Q09 financial results
#msg-42490961 Humira continues on monster pace
#msg-35632310 Feb 2009 feature in Barron’s


Acquisitions
#msg-34774636 Jan 2009 feature in WSJ
#msg-41922225 Solvay drug unit, including TriLipix
#msg-41374735 Evalve
#msg-41143330 Visiogen
#msg-34762429 Advanced Medical Optics (Allergan spin-off)
#msg-34244326 Ibis Biosciences (former ISIS subsidiary)
#msg-14553895 Kos Pharmaceuticals
#msg-10772808 Guidant’s vascular business (PR)
#msg-9314269 Guidant’s vascular business (commentary)


Cholesterol franchise including JV with AZN
#msg-38449725 ABT, AZN submit NDA for Certriad
#msg-33503193 TriLipix 1-Year combo data
#msg-33263372 Crestor JUPITER data could be game-changer
#msg-34203456 FDA approves TriLipix
#msg-26869744 FDA approves Simcor
#msg-30170058 MRK’s Cordaptive delayed until 2013
#msg-28510348 Heart disease: Not about cholesterol?
#msg-39401238 Niaspan vs Zetia trial halted—results pending
#msg-38554134 Niaspan lowers level of lipoprotein


Drug business (general)
#msg-42490961 Humira continues on monster pace
#msg-39417561 Size and segments of US market for RA
#msg-26156472 FDA approves Humira for plaque psoriasis
#msg-29106939 ABT showcases ADHD portfolio
#msg-38562229 FDA requests new Flutiform trial


Xience
#msg-39762286 2Q09 DES sales and market shares
#msg-32873087 Xience ramp exceeds forecasts (1)
#msg-32217694 Xience ramp exceeds forecasts (2)
#msg-42404723 Xience bests Taxus in ‘real world’ SPIRIT IV
#msg-41731638 Xience blows away Taxus at three years in SPIRIT III
#msg-41855797 Xience beats Taxus Liberté with ease
#msg-38097301 Xience shines in hard-to-treat subgroups
#msg-30452522 FDA approves Xience
#msg-38985789 EU approves Xience Prime
#msg-41529862 Xience approved in China
#msg-39903651 ABT wins $400M patent settlement from MDT


Bioabsorbable stent
#msg-36509882 Clinical program for bioabsorbable DES
#msg-36292361 WSJ blurb (Mar 2009)
#msg-32869939 Business Week feature (Oct 2008)


Corporate and miscellaneous
#msg-35753218 ABT hikes dividend for 37th consecutive year!
#msg-32844386 New $5B buyback authorization
#msg-39161889 Jury hits ABT with $1.7B award in Humira suit
#msg-43335667 Judge refuses to reduce Humira damages
#msg-40949294 Cancer-biomarker collaboration with PFE
#msg-39511634 Cancer-biomarker collaboration with GSK
#msg-31637906 ABT cuts 1,000 jobs
#msg-29708517 Musings on TriCor patent case
#msg-31102936 Musings on Norvir lawsuit
#msg-37562781 ABT sues JNJ on Simponi patent